It is believed that beta-adrenergic blockade increases the outflow facility in animals, and the tonographic data so far obtained indicate that propranolol does so also in man (Perpignano, I968; Bonomi and Carli, I972; Bucci and Romani, I972).
Nevertheless, considerations based on different grounds seem to indicate support for other modes of action (Virno, Marinosci, Pecori Giraldi, and Missiroli, I969; Takafts, SzilvAssy, and Kerek, 1972) .
Furthermore, the ability of propranolol to reduce intraocular pressure has been ascribed to actions of the drug that are distinct from the beta-blocking effect, namely, to its surface anaesthetic or quinidinelike properties (Musini and others, I971; Vale and Phillips, 1970) .
The study of the ocular effects of other betareceptor antagonists may offer more information on the action mechanism of this group of drugs which may become interesting both theoretically and practically.
The drug selected for the present study was pindolol (L.B. 46, Visken) . The beta-blocking action of pindolol was first reported by Saameli (i 967), see This compound has the following properties:
(a) Beta-blocking activity on the guinea-pig heart 20 to 40 times stronger than propranolol (Clark and Saameli, 1970) All the differences are highly significant, except those found at I 8 and 24 hours in the groups of normal eyes. Table III shows the tonographic results obtained in the single instillation experiment. In both normal and glaucomatous eyes the treatment produced a clear and highly significant lowering of the intraocular pressure, while no effect on the outflow was seen.
In Table IV the results of the long-term experiment are summarized.
After one week of treatment the pressure-lowering effect was clear and the outflow facility unaffected. After one month, however, although the reduction of pressure was of the same order of magnitude, a slight but significant increase in outflow appeared.
Discussion
The results of our study clearly demonstrate that pindolol lowers the intraocular pressure in normal eyes and, to a greater extent, in eyes suffering from open-angle glaucoma.
This effect is not at first accompanied by any significant variation in the outflow facility. It is, therefore, most probably to be ascribed to inhibition of aqueous humour production. Only after one month of treatment does an increase in outflow facility appear.
It is noteworthy that also at that time the variation of facility is too small to explain the lowering of pressure, and that no more than one-third of the effect on intraocular pressure can be ascribed to it.
Thus, pindolol seems to act in a different way from propranolol, the action of which has been found to Effect ofpindolol on intraocular pressure 303 consist of an increase of outflow facility. This may be explained by the different properties of the two drugs. Pindolol indeed has a higher beta-blocking effect, a higher intrinsic beta-mimetic action, less quinidine-like effect, and no surface activity.
Recently Bucci and Romani (1972) explained the action mechanism of propranolol as being due to an alteration in balance between the alpha-and betaadrenergic receptors in the eye, with prevalence of the alpha effects and consequently an increase of outflow facility.
The observation of the lack of effect on facility in the first phase of the action of pindolol makes this explanation unsatisfactory for a general interpretation of the effect of beta-blockers on intraocular pressure. The problem seems to be more complex and needs further investigation. Nevertheless, on practical grounds, pindolol seems to be potentially useful in the treatment of glaucomas. Its strong tension-lowering effect, its lack of action on the pupil and on the corneal sensitivity, and its easy tolerance make it, in our opinion, a very good drug for topical use, deserving a larger trial.
We have no evidence of any toxic effect of pindolol on the eye. However, since practolol, another betablocking agent, has shown a damaging effect on the eye when given systemically (Wright, 1974) , the possibility of a similar danger cannot yet be ruled out.
Summary
Pindolol, a strong beta-adrenergic blocking agent, instilled into the conjunctival sac of normal and glaucomatous eyes, produced a significant drop in intraocular pressure.
This was not, at first, accompanied by any variation in outflow facility; only after prolonged treatment did an increase in facility appear, which accounted only for one-third of the tension-lowering effect.
The drug was well tolerated, and did not affect either pupil motility or corneal sensitivity. It seems suitable for a trial use in the treatment of glaucoma.
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